P&T Committee Meeting Information
Upcoming Meetings
Dates
- Wednesday, September 24, 2025; 12-4 p.m.
- Thursday, September 25, 2025; 9 a.m.-4 p.m.
Location
- The September P&T Committee meetings will be held virtually.
Register
- Register for the DHS Pharmacy & Therapeutics Committee meeting on September 24, 2025.
- Register for the DHS Pharmacy & Therapeutics Committee meeting on September 25, 2025.
Public Testimony
- All members of the public may register to provide verbal or written testimony related to a drug or class of drugs included on the Statewide PDL at the P&T Committee meetings.
- Registration to present testimony during the meetings must be received by Wednesday, September 10, 2025. To register, please go to the Pennsylvania Medical Assistance Preferred Drug List website and select "Public Testimony Registration." Please include the drug or class of drugs you wish to speak on. You will receive a confirmation email for your public testimony registration, which will be a separate from the email containing your webinar registration details.
- Written testimony will be accepted and must be submitted by Wednesday, September 10, 2025. The written testimony will be distributed to all P&T Committee members prior to the meetings. Written testimony should be emailed to RA-PharmForms@pa.gov. You will receive a confirmation email that your written testimony has been received.
This is a preliminary list of drug classes for review. Additional classes may be added prior to the meeting. Please check back regularly for updates.
- Acne Agents, Oral
- Acne Agents, Topical
- Alcohol Use Disorder Agents
- Alzheimer's Agents
- Analgesics, Non-Opioid Barbiturate Combinations
- Analgesics, Opioid Long-Acting
- Analgesics, Opioid Short-Acting
- Androgenic Agents
- Angiotensin Modulator Combinations
- Angiotensin Modulators
- Antianginal Agents
- Antibiotics, GI and Related Agents
- Antibiotics, Inhaled
- Antibiotics, Topical
- Anticoagulants
- Anticonvulsants
- Antidepressants, Other
- Antidepressants, SSRIs
- Antiemetics/Antivertigo Agents
- Antifungals, Oral
- Antifungals, Topical
- Antihemophilia Agents
- Antihistamines, Minimally Sedating
- Antihypertensives, Sympatholytic
- Antihyperuricemics
- Antimalarials
- Antiparasitics, Topical
- Antiparkinson's Agents
- Antipsoriatics, Oral
- Antipsoriatics, Topical
- Antipsychotics
- Antivirals, CMV
- Antivirals, Herpes
- Antivirals, Influenza
- Anxiolytics
- Benign Prostatic Hyperplasia (BPH) Treatments
- Beta Blockers
- Bladder Relaxant Preparations
- Bone Density Regulators
- Botulinum Toxins
- Bronchodilators, Beta Agonists
- Calcium Channel Blockers
- Cephalosporins
- Colony Stimulating Factors
- Continuous Glucose Monitoring Products
- Contraceptives, Oral
- Contraceptives, Other
- COPD Agents
- Cytokine and CAM Antagonists
- Dry Eye Treatments
- Enzyme Replacements, Gaucher Disease
- Epinephrine, Self-Administered
- Erythropoiesis Stimulating Agents
- Estrogens
- Fluoroquinolones, Oral
- GI Motility, Chronic Agents
- Glucocorticoids, Inhaled
- Glucocorticoids, Oral
- Growth Hormones
- H. Pylori Treatments
- Hematopoietic Mixtures
- Hepatic and Biliary Agents
- Hepatitis B Agents
- Hepatitis C Agents
- Hereditary Angioedema (HAE) Treatments
- Histamine 2 Receptor Blockers
- HIV/AIDS Antiretrovirals
- Hypoglycemia Treatments
- Hypoglycemics, Alpha-Glucosidase Inhibitors
- Hypoglycemics, Insulin and Related Agents
- Hypoglycemics, Meglitinides
- Hypoglycemics, Metformins
- Hypoglycemics, SGLT2 Inhibitors
- Hypoglycemics, Sulfonylureas
- Hypoglycemics, TZDs
- Immunomodulators, Dermatologics
- Immunomodulators, Topical
- Immunosuppressives, Oral
- Intra-Articular Hyaluronates
- Intranasal Rhinitis Agents
- Iron Chelating Agents
- Iron, Parenteral
- Leukotriene Modifiers
- Lipotropics, Other
- Lipotropics, Statins
- Local Anesthetics, Topical
- Macrolides
- Macular Degeneration Agents
- Methotrexate
- Migraine Acute Treatment Agents
- Migraine Prevention Agents
- Monoclonal Antibodies (MABs) - Anti-IL, Anti-IgE, Anti-TSLP
- Multiple Sclerosis Agents
- Neuropathic Pain Agents
- NSAIDs
- Oncology Agents, Breast Cancer
- Oncology Agents, Oral
- Ophthalmics, Allergic Conjunctivitis
- Ophthalmics, Antibiotics
- Ophthalmics, Antibiotic-Steroid Combinations
- Ophthalmics, Anti-Inflammatories
- Ophthalmics, Glaucoma
- Opioid Overdose Agents
- Opioid Use Disorder Treatments
- Otic Antibiotic Preparations
- Pancreatic Enzymes
- Penicillins
- Phosphate Lowering Agents
- Pituitary Suppressive Agents, LHRH
- Platelet Aggregation Inhibitors
- Potassium Removing Agents
- Prenatal Vitamins
- Progestational Agents
- Proton Pump Inhibitors (PPIs)
- Pulmonary Hypertension Agents, Oral and Inhaled
- Sedative Hypnotics
- Sickle Cell Anemia Agents
- Skeletal Muscle Relaxants
- Smoking Cessation Products
- Steroids, Topical
- Stimulants and Related Agents
- Tetracyclines
- Thalidomide and Derivatives
- Thrombopoietics
- Thyroid Hormones
- Tubeless Insulin Delivery Devices
- Ulcerative Colitis Agents
- Urea Cycle Disorder Agents
- Urinary Anti-Infectives
- Vaginal Anti-Infectives
- Vitamin D Analogs
- VMAT2 Inhibitors
- Past Pharmacy and Therapeutics Committee Meetings
- Review the Pharmacy and Therapeutics Committee By-Laws
Related Links
The Department of Human Services (Department) appointed the P&T Committee to act in an advisory capacity to the Department and the Office of Medical Assistance Programs (OMAP) and provide an unbiased clinical perspective on the Department's Statewide Preferred Drug List (PDL). Recommendations from the committee must be reviewed and approved by the Secretary of the Department of Human Services.
Change Healthcare provides clinical and financial analysis support to the P&T Committee.
Committee Information
Composition and responsibilities of the committee:
- Comprised of department medical directors, external physicians, pharmacists, consumer advocates, and specialists as needed for drug class reviews.
- Recommend a clinically-based PDL with an emphasis on effectiveness, safety, and outcomes.
- Recommend prior authorization guidelines for non-preferred drugs as well as certain preferred drugs using current community standards for prescribing.
- Recommend Prospective and Retrospective Drug Utilization Review Program Review and Development.
Name | Specialty | Independent* | Department** | MCO |
|---|---|---|---|---|
Ivonne Acrich, MD | OMHSAS Child/Adolescent Psychiatrist |
| X |
|
Christopher Antypas, PharmD | Community Pharmacist | X |
|
|
Lawrence Appel, MD, SFHM | Medical Director, Office of Long Term Living |
| X |
|
Terri Cathers, PharmD, | OMAP Pharmacy Director |
| X |
|
Sharon Connor, PharmD | Academic Pharmacist | X |
|
|
Molly DiMatteo, DO | Family Practitioner | X | | |
Oluwatoyin Fadeyibi, PharmD, MPH | Community Behavioral Health Pharmacist | | | X |
Andrea Fox, MD | Internist | X |
|
|
Mark Fuller, MD | Carelon Health of PA Medical Director | X | ||
Donald Gerhart, RPh | Community Pharmacist | X |
|
|
James Hancovsky, RPh, MBA | United Health Care Pharmacy Director |
|
| X |
| Van Hellerslia, PharmD, BCPS | Consumer Representative | X | ||
David Kelley, MD | OMAP Chief Medical Officer, Office of Medical Assistance Programs | | X | |
| Chen Kenyon, MD, MSHP | Pediatrician | X | ||
Peter Kreckel, RPh | Community Pharmacist | X |
|
|
Renee Licwinko, RPh | Highmark Wholecare Pharmacist |
|
| X |
| Michelle Murphy, PharmD, Specialty | AmeriHealth Caritas & Keystone First HealthChoices & Community HealthChoices Pharmacist | X | ||
Michele Musheno, RPh, MS | Academic/Hospital Pharmacist | X |
|
|
Geoffrey Neimark, MD | Community Care Behavioral Health Psychiatrist | | | X |
Ian Paul, MD, Vice Chair | Pediatrician | X |
|
|
Adam Raphael Rom, MD | Family Practitioner | X |
|
|
Amy Saracino, DO | OMHSAS Adult Psychiatrist |
| X |
|
| John Shand, MD | PerformCare PA Medical Director | X | ||
| Jason Skaria, PharmD | PA Health & Wellness Pharmacist | X | ||
Christopher Squillaro, DO | Magellan Behavioral Health of PA Medical Director | | | X |
Kevin Szczecina, RPh | Geisinger Health Plan Pharmacist |
|
| X |
Fallan Vaisberg, PharmD, RPh | Health Partners Plans Formulary Pharmacist | | | X |
Andreas Wali, MD | Cardiologist | X | | |
Verlyn Warrington, MD | Bariatric Medicine Specialist/Family Medicine Doctor | X |
|
|
Lloyd Wertz | Consumer/Family Advocate | X |
|
|
Lauren Zandier, PharmD | UPMC For You Pharmacist | | | X |
* - Independent Members are not employed by the Department
** - Department Members are employed by the Department on a full or part-time basis
Effective December 6, 2024 / Last modified March 20, 2025